Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
MMP20 Biologics Sequence Review Report 2026: Matrix metalloproteinase-20 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of MMP20 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MMP19 Biologics Sequence Review Report 2026: Matrix metalloproteinase-19 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of MMP19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MMP14 Biologics Sequence Review Report 2026: Matrix metalloproteinase-14 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of MMP14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
LRPAP1 Biologics Sequence Review Report 2026: Alpha-2-macroglobulin receptor-associated protein Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of LRPAP1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
LRP5L Biologics Sequence Review Report 2026: Low-density lipoprotein receptor-related protein 5-like protein Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of LRP5L protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LRP11 Biologics Sequence Review Report 2026: Low-density lipoprotein receptor-related protein 11 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of LRP11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRG2 Biologics Sequence Review Report 2026: Killer cell lectin-like receptor subfamily G member 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of KLRG2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRG1 Biologics Sequence Review Report 2026: Killer cell lectin-like receptor subfamily G member 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of KLRG1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRF2 Biologics Sequence Review Report 2026: Killer cell lectin-like receptor subfamily F member 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of KLRF2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KLRF1 Biologics Sequence Review Report 2026: Killer cell lectin-like receptor subfamily F member 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of KLRF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
ILKAP Biologics Sequence Review Report 2026: Integrin-linked kinase-associated serine/threonine phosphatase 2C Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ILKAP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
ILF2 Biologics Sequence Review Report 2026: Interleukin enhancer-binding factor 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of ILF2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.